Sponsors Seek More Clarity in Draft Guidance on Patient-Focused Drug Development

Multiple comments on the FDA’s efforts to provide guidance on how sponsors can develop patient-focused clinical outcome assessments (COA) for regulatory decision-making called for more clarity on one of the four types of COA — patient reported outcomes (PRO) — and on using digital health technology (DHT) for COA data.
Source: Drug Industry Daily